Abstract
The Food and Drug Administration in the US recently granted premarket clearance for a DNA sequencing platform with increased diagnostic power. Collins et al. stated in an editorial in the New England Journal of Medicine that this approval may open the door “for the development and use of innumerable new genome-based tests” (Collins et al., NEJM 369:2369–2371, 2013). Collins et al. called the approval “a landmark move that will finally open the way to realize the promise of personalized medicine” (Collins et al., NEJM 369:2369–2371, 2013).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Collins F.S, et al. 2013. First FDA Authorization for next-generation sequencer. NEJM 369(25): 2369–2371. doi:10.1056/NEJM.
Mascalzoni D., et al. 2013. Rare diseases and now rare data. Nature Reviews Genetics 14: 372. doi:10.1038/nrg3494.
Mascalzoni D., et al. 2014. Rare diseases research; breaking the privacy barriers. Applied and Translational Genomics 3(2): 23–29.
McNally, E., et al. 2004. Ethical, legal and social aspects of genetic testing: research, development and clinical applications. Brussels: Research Directorate General of the European Commission.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Mascalzoni, D. (2015). Ethics Law and Governance of Biobanking: A Very Complex Normative Puzzle. In: Mascalzoni, D. (eds) Ethics, Law and Governance of Biobanking. The International Library of Ethics, Law and Technology, vol 14. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9573-9_1
Download citation
DOI: https://doi.org/10.1007/978-94-017-9573-9_1
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-9572-2
Online ISBN: 978-94-017-9573-9
eBook Packages: MedicineMedicine (R0)